AR088755A1 - Formas solidas de un inhibidor de disociacion transtiretina - Google Patents
Formas solidas de un inhibidor de disociacion transtiretinaInfo
- Publication number
- AR088755A1 AR088755A1 ARP120103410A ARP120103410A AR088755A1 AR 088755 A1 AR088755 A1 AR 088755A1 AR P120103410 A ARP120103410 A AR P120103410A AR P120103410 A ARP120103410 A AR P120103410A AR 088755 A1 AR088755 A1 AR 088755A1
- Authority
- AR
- Argentina
- Prior art keywords
- solid forms
- transtiretin
- disociation
- inhibitor
- crystalline form
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 abstract 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 2
- 229960003194 meglumine Drugs 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535551P | 2011-09-16 | 2011-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088755A1 true AR088755A1 (es) | 2014-07-02 |
Family
ID=47116132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103410A AR088755A1 (es) | 2011-09-16 | 2012-09-14 | Formas solidas de un inhibidor de disociacion transtiretina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9249112B2 (enExample) |
| EP (1) | EP2755961A1 (enExample) |
| JP (2) | JP5869677B2 (enExample) |
| KR (1) | KR20140054231A (enExample) |
| CN (1) | CN103781770B (enExample) |
| AR (1) | AR088755A1 (enExample) |
| AU (1) | AU2012310157B2 (enExample) |
| BR (1) | BR112014005810A2 (enExample) |
| CA (1) | CA2847293C (enExample) |
| IL (1) | IL231472A0 (enExample) |
| MX (1) | MX2014003043A (enExample) |
| RU (1) | RU2586330C2 (enExample) |
| SG (1) | SG2014013270A (enExample) |
| TW (2) | TWI476185B (enExample) |
| WO (1) | WO2013038351A1 (enExample) |
| ZA (1) | ZA201401202B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06105459B2 (ja) * | 1988-08-11 | 1994-12-21 | 日本電気株式会社 | ベクトル処理装置 |
| SG2014013270A (en) * | 2011-09-16 | 2014-05-29 | Pfizer | Solid forms of a transthyretin dissociation inhibitor |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| PT3191461T (pt) * | 2014-09-08 | 2021-12-27 | Pfizer | Formas sólidas cristalinas de 6-carboxi-2-(3,5- diclorofenil)-benzoxazol |
| CN107344927A (zh) * | 2016-05-05 | 2017-11-14 | 苏州晶云药物科技有限公司 | Tafamidis葡甲胺盐的晶型E及其制备方法和用途 |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| WO2020128816A2 (en) | 2018-12-20 | 2020-06-25 | Pfizer Inc. | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent |
| PL3953339T3 (pl) * | 2019-04-11 | 2025-05-05 | Inke, S.A. | Proces otrzymania 1-deoksy-1-metyloamino-d-glucitolu 2-(3,5-dichlorofenylo)-6-benzoksazolokarboksylanu |
| US12391656B2 (en) | 2019-05-16 | 2025-08-19 | Assia Chemical Industries Ltd. | Solid state forms of Tafamidis and salts thereof |
| MX2021014682A (es) * | 2019-05-31 | 2022-04-06 | Plex Pharmaceuticals Inc | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. |
| WO2021019448A1 (en) * | 2019-08-01 | 2021-02-04 | Honour (R&D) | Process for the preparation of transthyretin dissociation inhibitor |
| EP4059926A4 (en) | 2019-11-15 | 2022-12-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF |
| EP4077287B1 (en) * | 2019-12-20 | 2025-11-19 | Pfizer Ireland Pharmaceuticals Unlimited Company | Efficient process for making 6-carboxy benzoxazole derivatives |
| WO2021232619A1 (zh) * | 2020-05-19 | 2021-11-25 | 苏州科睿思制药有限公司 | 一种他发米帝司游离酸的晶型及其制备方法和用途 |
| US20230265059A1 (en) * | 2020-07-04 | 2023-08-24 | Nuray Chemicals Private Limited | Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof |
| FR3114230B1 (fr) | 2020-09-23 | 2022-12-23 | Pierre Berger | Dispositif de connexion entre une toile et un rail |
| WO2022084790A1 (en) * | 2020-10-19 | 2022-04-28 | Glenmark Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
| WO2022112919A1 (en) | 2020-11-25 | 2022-06-02 | Pfizer Inc. | (aza)benzothiazolyl substituted pyrazole compounds |
| EP4083027A1 (en) | 2021-04-26 | 2022-11-02 | Química Sintética, S.A. | A solid state form of tafamidis and a process for its preparation |
| WO2023020762A1 (en) | 2021-08-16 | 2023-02-23 | Synthon B.V. | Crystalline forms of tafamidis nicotinamide adduct |
| JP2024541422A (ja) | 2021-11-17 | 2024-11-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | タファミジスの固体状態の形態 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602336C (de) | 1933-03-09 | 1934-09-06 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe |
| US3551433A (en) | 1967-06-21 | 1970-12-29 | Us Army | Preparation of 4-phenyl-4-acyloxypiperidine |
| US3551443A (en) | 1968-10-30 | 1970-12-29 | Ciba Ltd | 2-phenylbenzoxazole derivatives |
| USRE29608E (en) | 1972-05-18 | 1978-04-11 | Lilly Industries Limited | Benzoxazole derivatives |
| DE2314238A1 (de) | 1973-03-22 | 1974-09-26 | Henkel & Cie Gmbh | Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen |
| US4025637A (en) | 1973-10-23 | 1977-05-24 | Lilly Industries, Ltd. | 2,5 OR 2,6 Disubstituted benzoxazoles |
| GB1488003A (en) * | 1973-10-23 | 1977-10-05 | Lilly Industries Ltd | 1,2-benzisoxazole derivatives processes for their preparation and their use as pharmaceuticals |
| US4025636A (en) | 1973-10-23 | 1977-05-24 | Lilly Industries, Ltd. | 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles |
| DE2619547A1 (de) | 1976-05-04 | 1977-11-24 | Dynamit Nobel Ag | Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen |
| US4416892A (en) | 1981-04-23 | 1983-11-22 | Lilly Industries Limited | Method of treating hypersensitivity disease with benzoxazole derivatives |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| DE4011106A1 (de) | 1990-04-06 | 1991-10-10 | Bayer Ag | Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US5254692A (en) | 1990-04-06 | 1993-10-19 | Bayer Aktiengesellschaft | 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines |
| US5037842A (en) | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| CA2051518A1 (en) | 1990-10-01 | 1992-04-02 | Robert J. Perry | Synthesis of heterocyclic compounds |
| CH681806A5 (enExample) | 1991-03-19 | 1993-05-28 | Ciba Geigy Ag | |
| US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| DE4304650A1 (de) | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
| US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| US5837390A (en) | 1995-05-10 | 1998-11-17 | Sony Corporation | Metal complex, method for producing the same and optical device |
| WO1998027972A2 (en) | 1996-12-23 | 1998-07-02 | Texas A & M University | Anti-amyloidogenic agents |
| FR2767527B1 (fr) | 1997-08-25 | 1999-11-12 | Pf Medicament | Derives de piperazines indoliques, utiles comme medicaments et procede de preparation |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| ATE244241T1 (de) | 1998-02-04 | 2003-07-15 | Univ Texas | Hemmung der menschlichen telomerase durch g- quadruplex interaktionverbindung |
| US6107491A (en) | 1998-07-20 | 2000-08-22 | Ciba Specialty Chemicals Corporation | Polymerizable diketopyrrolopyrroles |
| GB9816654D0 (en) | 1998-07-30 | 1998-09-30 | Zeneca Ltd | Chemical compounds |
| WO2000078733A1 (de) | 1999-06-18 | 2000-12-28 | Bayer Aktiengesellschaft | Phenoxyfluorpyrimidine |
| US6420418B1 (en) | 1999-08-16 | 2002-07-16 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
| GB9919673D0 (en) | 1999-08-20 | 1999-10-20 | Cancer Res Campaign Tech | 2-Arlybenzazole compounds |
| JP2001226358A (ja) | 1999-10-12 | 2001-08-21 | Japan Tobacco Inc | Ｌｐｌ活性増強剤 |
| CN1241909C (zh) | 2000-03-16 | 2006-02-15 | 弗·哈夫曼-拉罗切有限公司 | 用作ip拮抗剂的羧酸衍生物 |
| GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
| EP2264018B1 (en) | 2000-08-24 | 2015-02-11 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Thioflavin derivatives for use in the diagnosis of Alzheimer's disease |
| JP3786203B2 (ja) | 2000-11-04 | 2006-06-14 | アベンティス・フアーマ・リミテッド | 置換アルカン酸 |
| WO2002046168A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| US7045539B2 (en) | 2000-12-22 | 2006-05-16 | Astrazeneca Ab | Therapeutic benzoxazole compounds |
| GB0118357D0 (en) | 2001-07-27 | 2001-09-19 | Syngenta Ltd | Chemical compounds |
| WO2003020698A2 (en) | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
| US6602619B2 (en) | 2001-10-19 | 2003-08-05 | Lightronik Technology Inc. | Organic EL device |
| US7253154B2 (en) | 2001-11-16 | 2007-08-07 | Nippon Chemiphar Co., Ltd. | Substituted thiazolopyrimidines as xanthine oxidase inhibitors |
| AU2002353739A1 (en) | 2001-11-28 | 2003-06-10 | Astrazeneca Ab | Therapeutic compounds |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| MXPA04005864A (es) | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Derivados de charcona y su uso para tratar enfermedades. |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| GB0205256D0 (en) | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
| AU2003237787B2 (en) | 2002-03-20 | 2008-12-18 | Metabolex, Inc. | Substituted phenylacetic acids |
| UA79755C2 (en) | 2002-04-16 | 2007-07-25 | Bayer Pharmaceuticals Corp | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| GB0226822D0 (en) | 2002-11-16 | 2002-12-24 | Oxford Glycosciences Uk Ltd | Novel compounds |
| DK1587821T6 (da) | 2002-12-19 | 2025-05-26 | Scripps Research Inst | Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning |
| JP2006517925A (ja) | 2003-01-14 | 2006-08-03 | メルク エンド カムパニー インコーポレーテッド | Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体 |
| CA2438032C (en) | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| CN101468965A (zh) | 2003-03-24 | 2009-07-01 | 默克公司 | 联芳基取代的6元杂环钠通道阻滞剂 |
| CN101333192A (zh) | 2003-04-03 | 2008-12-31 | 默克公司 | 作为钠通道阻滞剂的联芳基取代吡唑 |
| JP2006523701A (ja) | 2003-04-18 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2005112913A1 (en) | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
| WO2011116123A1 (en) | 2010-03-19 | 2011-09-22 | Irm Llc | Tafamidis for the treatment of ophthalmic diseases |
| SG2014013270A (en) * | 2011-09-16 | 2014-05-29 | Pfizer | Solid forms of a transthyretin dissociation inhibitor |
| WO2013166041A1 (en) | 2012-05-01 | 2013-11-07 | The Trustees Of Columbia University In The City Of New York | Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
-
2012
- 2012-09-12 SG SG2014013270A patent/SG2014013270A/en unknown
- 2012-09-12 CA CA2847293A patent/CA2847293C/en not_active Expired - Fee Related
- 2012-09-12 CN CN201280043084.6A patent/CN103781770B/zh not_active Expired - Fee Related
- 2012-09-12 KR KR1020147006603A patent/KR20140054231A/ko not_active Ceased
- 2012-09-12 RU RU2014109676/04A patent/RU2586330C2/ru not_active Application Discontinuation
- 2012-09-12 JP JP2014530354A patent/JP5869677B2/ja not_active Expired - Fee Related
- 2012-09-12 MX MX2014003043A patent/MX2014003043A/es unknown
- 2012-09-12 EP EP12780287.4A patent/EP2755961A1/en not_active Withdrawn
- 2012-09-12 WO PCT/IB2012/054748 patent/WO2013038351A1/en not_active Ceased
- 2012-09-12 AU AU2012310157A patent/AU2012310157B2/en active Active
- 2012-09-12 US US14/345,111 patent/US9249112B2/en not_active Expired - Fee Related
- 2012-09-12 BR BR112014005810A patent/BR112014005810A2/pt active Search and Examination
- 2012-09-14 TW TW101133893A patent/TWI476185B/zh not_active IP Right Cessation
- 2012-09-14 TW TW104101710A patent/TWI538909B/zh not_active IP Right Cessation
- 2012-09-14 AR ARP120103410A patent/AR088755A1/es unknown
-
2014
- 2014-02-18 ZA ZA2014/01202A patent/ZA201401202B/en unknown
- 2014-03-12 IL IL231472A patent/IL231472A0/en unknown
-
2015
- 2015-12-22 US US14/979,021 patent/US20160185739A1/en not_active Abandoned
-
2016
- 2016-01-07 JP JP2016001888A patent/JP2016128444A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014109676A (ru) | 2015-10-27 |
| TWI476185B (zh) | 2015-03-11 |
| US9249112B2 (en) | 2016-02-02 |
| NZ621194A (en) | 2016-02-26 |
| RU2586330C2 (ru) | 2016-06-10 |
| SG2014013270A (en) | 2014-05-29 |
| CN103781770A (zh) | 2014-05-07 |
| IL231472A0 (en) | 2014-04-30 |
| US20150031735A1 (en) | 2015-01-29 |
| WO2013038351A1 (en) | 2013-03-21 |
| JP2014526498A (ja) | 2014-10-06 |
| KR20140054231A (ko) | 2014-05-08 |
| TW201516039A (zh) | 2015-05-01 |
| US20160185739A1 (en) | 2016-06-30 |
| ZA201401202B (en) | 2016-01-27 |
| EP2755961A1 (en) | 2014-07-23 |
| TWI538909B (zh) | 2016-06-21 |
| CA2847293A1 (en) | 2013-03-21 |
| CN103781770B (zh) | 2016-04-13 |
| TW201315720A (zh) | 2013-04-16 |
| AU2012310157A1 (en) | 2014-04-03 |
| CA2847293C (en) | 2017-03-28 |
| JP5869677B2 (ja) | 2016-02-24 |
| HK1197239A1 (zh) | 2015-01-09 |
| MX2014003043A (es) | 2015-02-05 |
| AU2012310157B2 (en) | 2015-11-12 |
| JP2016128444A (ja) | 2016-07-14 |
| BR112014005810A2 (pt) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| FI3351539T3 (fi) | Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| MX374012B (es) | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol. | |
| AR094193A1 (es) | Productos de higiene bucal que comprenden oxido de zinc y trimetilglicina | |
| AR099354A1 (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos | |
| ES2421956B1 (es) | Nueva forma cristalina de sulfato de sitagliptina | |
| AR094842A1 (es) | Formas sólidas de un inhibidor cdk4/6 selectivo | |
| AR082804A1 (es) | Formas cristalinas de un inhibidor del factor xa | |
| UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
| CL2014000209A1 (es) | Metodo para tratar esclerosis multiple que comprende el uso de laquinimod y acetato de glatiramero y kit que comprende composiciones farmaceuticas conteniendo a ambos compuestos independientemente. | |
| BR112015002767A2 (pt) | composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| PE20140698A1 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2, 4-diamina | |
| CL2013000444A1 (es) | Composicion farmaceutica oral de liberacion prolongada que comprende un material de liberacion prolongada, y oxicodona y naloxona, cuya composicion farmaceutica almacenada en condiciones de estres tiene menos de un 4% de sustancias relacionadas con oxicodona y naloxona; y uso de un aglutinante para fabricar dicha composicion. | |
| CR20110457A (es) | Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma | |
| CL2013002033A1 (es) | Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar. | |
| BR112015002706A2 (pt) | niclosamida e seus derivados para uso no tratamento de tumores sólidos | |
| UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
| CL2014002986A1 (es) | Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k. | |
| BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
| PE20130212A1 (es) | Formas polimorficas de st-246 y metodos de preparacion | |
| CL2014001399A1 (es) | Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |